Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety
Research on effects of anti-hepatitis B virus (HBV) nucleoside analogs on male fertility and birth defects is limited and safety of nucleoside analogs in pregnancy is still a concern. Chronic hepatitis B (CHB) patients in Guangdong province were surveyed using a structured questionnaire. We collecte...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2019/9703907 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551889251598336 |
|---|---|
| author | Zhao X. Hu Yi N. Ye Wei G. Wu Xu J. Liang Qi W. Wu Ao Zhang Xing R. Zheng Zhi L. Gao Liang Peng Chan Xie |
| author_facet | Zhao X. Hu Yi N. Ye Wei G. Wu Xu J. Liang Qi W. Wu Ao Zhang Xing R. Zheng Zhi L. Gao Liang Peng Chan Xie |
| author_sort | Zhao X. Hu |
| collection | DOAJ |
| description | Research on effects of anti-hepatitis B virus (HBV) nucleoside analogs on male fertility and birth defects is limited and safety of nucleoside analogs in pregnancy is still a concern. Chronic hepatitis B (CHB) patients in Guangdong province were surveyed using a structured questionnaire. We collected data including medication type, fertility, and birth defects. Moreover, a survey of the knowledge of antiviral nucleoside analogs safety in fertility of male patients was conducted among physicians nationwide. Semen samples of 30 patients were collected. We screened 1050 HBV-positive male patients. Reasons for not receiving antivirals in 150 patients were “did not meet criteria for antiviral therapy,” fertility, and financial. Furthermore, 900 participants received antivirals (85.71%, 900/1050), including 792 patients with children and 15.15% (120/792) took anti-HBV treatment when preparing for pregnancy. Based on whether they received antiviral therapy during conception or not, we divided patients into two groups. In the child-bearing age group, 88.33% (106/120) of patients received telbivudine (LDT), whereas the other group mainly received entecavir (ETV) (87.20%, 586/672). No significant difference occurred in birth defect incidence rates between both groups. Furthermore, 558 physicians completed questionnaires. Reasons that influenced drug selection were “patient’s condition,” “fertility demand,” “financial condition,” and “compliance.” Telbivudine was the first-choice drug (32.80%, 183/558) while tenofovir (TDF) was the second (2.69%, 15/558). Additionally, 61.47% of physicians considered telbivudine or tenofovir as the first choice for male patients who met antiviral criteria, whereas 19% suggested delayed therapy and follow-up until childbirth. No significant changes occurred in semen volume, concentration, mobility, and percentage before and after administration of anti-HBV nucleoside analogs, which did not affect male fertility and birth defect incidence while the desire for pregnancy influenced drug selection and timing of administration. Further research on the effects of analogs on male fertility and fetal safety is required. |
| format | Article |
| id | doaj-art-89225b31b8964bf8870eb0dc402868da |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-89225b31b8964bf8870eb0dc402868da2025-02-03T06:00:10ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972019-01-01201910.1155/2019/97039079703907Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal SafetyZhao X. Hu0Yi N. Ye1Wei G. Wu2Xu J. Liang3Qi W. Wu4Ao Zhang5Xing R. Zheng6Zhi L. Gao7Liang Peng8Chan Xie9Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, ChinaDepartment of Infectious Diseases, The First People’s Hospital of Foshan, Foshan, Guangdong Province, ChinaKey Laboratory of Infection and Immunity, Institute of Hepatology, Shenzhen Third People’s Hospital, Shenzhen, Guangdong Province, ChinaDepartment of Infectious Disease, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong Province, ChinaDepartment of Infectious Disease, Zengcheng People’s Hospital, Guangzhou, Guangdong Province, ChinaDepartment of Nephrology, Guangdong Second Traditional Chinese Medicine Hospital, Guangzhou, Guangdong Province, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, ChinaResearch on effects of anti-hepatitis B virus (HBV) nucleoside analogs on male fertility and birth defects is limited and safety of nucleoside analogs in pregnancy is still a concern. Chronic hepatitis B (CHB) patients in Guangdong province were surveyed using a structured questionnaire. We collected data including medication type, fertility, and birth defects. Moreover, a survey of the knowledge of antiviral nucleoside analogs safety in fertility of male patients was conducted among physicians nationwide. Semen samples of 30 patients were collected. We screened 1050 HBV-positive male patients. Reasons for not receiving antivirals in 150 patients were “did not meet criteria for antiviral therapy,” fertility, and financial. Furthermore, 900 participants received antivirals (85.71%, 900/1050), including 792 patients with children and 15.15% (120/792) took anti-HBV treatment when preparing for pregnancy. Based on whether they received antiviral therapy during conception or not, we divided patients into two groups. In the child-bearing age group, 88.33% (106/120) of patients received telbivudine (LDT), whereas the other group mainly received entecavir (ETV) (87.20%, 586/672). No significant difference occurred in birth defect incidence rates between both groups. Furthermore, 558 physicians completed questionnaires. Reasons that influenced drug selection were “patient’s condition,” “fertility demand,” “financial condition,” and “compliance.” Telbivudine was the first-choice drug (32.80%, 183/558) while tenofovir (TDF) was the second (2.69%, 15/558). Additionally, 61.47% of physicians considered telbivudine or tenofovir as the first choice for male patients who met antiviral criteria, whereas 19% suggested delayed therapy and follow-up until childbirth. No significant changes occurred in semen volume, concentration, mobility, and percentage before and after administration of anti-HBV nucleoside analogs, which did not affect male fertility and birth defect incidence while the desire for pregnancy influenced drug selection and timing of administration. Further research on the effects of analogs on male fertility and fetal safety is required.http://dx.doi.org/10.1155/2019/9703907 |
| spellingShingle | Zhao X. Hu Yi N. Ye Wei G. Wu Xu J. Liang Qi W. Wu Ao Zhang Xing R. Zheng Zhi L. Gao Liang Peng Chan Xie Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety Canadian Journal of Gastroenterology and Hepatology |
| title | Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety |
| title_full | Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety |
| title_fullStr | Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety |
| title_full_unstemmed | Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety |
| title_short | Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety |
| title_sort | real life state of anti hepatitis b virus drug choice in child bearing age male patients and effect on fertility and fetal safety |
| url | http://dx.doi.org/10.1155/2019/9703907 |
| work_keys_str_mv | AT zhaoxhu reallifestateofantihepatitisbvirusdrugchoiceinchildbearingagemalepatientsandeffectonfertilityandfetalsafety AT yinye reallifestateofantihepatitisbvirusdrugchoiceinchildbearingagemalepatientsandeffectonfertilityandfetalsafety AT weigwu reallifestateofantihepatitisbvirusdrugchoiceinchildbearingagemalepatientsandeffectonfertilityandfetalsafety AT xujliang reallifestateofantihepatitisbvirusdrugchoiceinchildbearingagemalepatientsandeffectonfertilityandfetalsafety AT qiwwu reallifestateofantihepatitisbvirusdrugchoiceinchildbearingagemalepatientsandeffectonfertilityandfetalsafety AT aozhang reallifestateofantihepatitisbvirusdrugchoiceinchildbearingagemalepatientsandeffectonfertilityandfetalsafety AT xingrzheng reallifestateofantihepatitisbvirusdrugchoiceinchildbearingagemalepatientsandeffectonfertilityandfetalsafety AT zhilgao reallifestateofantihepatitisbvirusdrugchoiceinchildbearingagemalepatientsandeffectonfertilityandfetalsafety AT liangpeng reallifestateofantihepatitisbvirusdrugchoiceinchildbearingagemalepatientsandeffectonfertilityandfetalsafety AT chanxie reallifestateofantihepatitisbvirusdrugchoiceinchildbearingagemalepatientsandeffectonfertilityandfetalsafety |